RA Capital Management’s Avidity Biosciences RNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $206M | Buy |
7,266,031
+965,623
| +15% | +$27.4M | 3.48% | 5 |
|
|
2025
Q1 | $186M | Hold |
6,300,408
| – | – | 3.11% | 8 |
|
|
2024
Q4 | $183M | Hold |
6,300,408
| – | – | 2.44% | 10 |
|
|
2024
Q3 | $289M | Buy |
6,300,408
+900,000
| +17% | +$41.3M | 3.34% | 6 |
|
|
2024
Q2 | $221M | Buy |
5,400,408
+2,118,228
| +65% | +$86.5M | 2.92% | 9 |
|
|
2024
Q1 | $83.8M | Buy |
3,282,180
+827,647
| +34% | +$21.1M | 1.07% | 27 |
|
|
2023
Q4 | $22.2M | Sell |
2,454,533
-3,962,465
| -62% | -$35.9M | 0.35% | 47 |
|
|
2023
Q3 | $40.9M | Hold |
6,416,998
| – | – | 0.81% | 36 |
|
|
2023
Q2 | $71.2M | Hold |
6,416,998
| – | – | 1.34% | 22 |
|
|
2023
Q1 | $98.5M | Buy |
6,416,998
+962,465
| +18% | +$14.8M | 2.23% | 14 |
|
|
2022
Q4 | $121M | Buy |
5,454,533
+3,287,142
| +152% | +$72.9M | 2.45% | 12 |
|
|
2022
Q3 | $35.4M | Hold |
2,167,391
| – | – | 0.76% | 41 |
|
|
2022
Q2 | $31.5M | Hold |
2,167,391
| – | – | 0.84% | 35 |
|
|
2022
Q1 | $40M | Buy |
2,167,391
+1,743,775
| +412% | +$32.2M | 0.87% | 37 |
|
|
2021
Q4 | $10.1M | Hold |
423,616
| – | – | 0.18% | 80 |
|
|
2021
Q3 | $10.4M | Buy |
+423,616
| New | +$10.4M | 0.14% | 74 |
|